IL307381A - Diagnostic methods of prostate cancer - Google Patents

Diagnostic methods of prostate cancer

Info

Publication number
IL307381A
IL307381A IL307381A IL30738123A IL307381A IL 307381 A IL307381 A IL 307381A IL 307381 A IL307381 A IL 307381A IL 30738123 A IL30738123 A IL 30738123A IL 307381 A IL307381 A IL 307381A
Authority
IL
Israel
Prior art keywords
prostate cancer
diagnostic methods
diagnostic
methods
prostate
Prior art date
Application number
IL307381A
Other languages
English (en)
Hebrew (he)
Original Assignee
Advanced Accelerator Applications
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications, Novartis Ag filed Critical Advanced Accelerator Applications
Publication of IL307381A publication Critical patent/IL307381A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL307381A 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer IL307381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (1)

Publication Number Publication Date
IL307381A true IL307381A (en) 2023-11-01

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307381A IL307381A (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
CN117120100A (zh) 2023-11-24
JP2024514293A (ja) 2024-04-01
WO2022207906A1 (en) 2022-10-06
KR20230165761A (ko) 2023-12-05
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
IL308766A (en) Compositions and methods for treating prostate cancer
SG11202003402QA (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
IL285961A (en) Therapeutic RNA for prostate cancer
SI3518932T1 (sl) Zdravljenje raka prostate
IL288939A (en) Methods of treating cancer by targeting cold tumors
IL284850A (en) Methods of treating breast cancer with toctinib
IL265675A (en) Methods for diagnosis and treatment of prostate cancer resistant to abiraterone acetate-glucocorticoid or sensitive to metastatic castration
SG11202107017TA (en) Methods of treating cancer
IL300171A (en) Combined treatment against cancer
GB202108237D0 (en) Cancer methods
GB201917428D0 (en) Prostate cancer diagnostic
GB201910444D0 (en) Methods of diagnosing cancer
IL305780A (en) Cancer treatment methods
IL326327A (en) Treatment of prostate cancer
GB202107994D0 (en) Treatment of cancer
IL309487A (en) Methods for determining the effectiveness of cancer treatment
IL277743A (en) A method for diagnosing breast cancer
IL272390A (en) Cancer treatment methods
GB202011743D0 (en) Diagnosis of cancer
GB202001963D0 (en) Cancer therapy
PL4175639T3 (pl) Masitinib w leczeniu nowotworu gruczołu krokowego opornego na kastrację
HK40076959A (en) Methods of treating prostate cancer
HK40087831A (en) Methods of treating prostate cancer
GB202306028D0 (en) Prostate cancer
IL314798A (en) Prostate cancer treatment methods